AKARI THERAPEUTICS PLC-ADR (AKTX) Stock Income Statement
USA - NASDAQ:AKTX - US00972G2075 - ADR
1.11 USD
+0.35 (+45.96%)
1.12 USD
+0.01 (+0.9%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 12.79M | 16.65M | 16.81M | 23.09M | 17.21M | |||
| Research and Development | 2.87M | 8.27M | 8.02M | 11.88M | 12.20M | |||
| Selling, General, and Administrative Expenses | 9.92M | 9.66M | 11.36M | 13.53M | 8.08M | |||
| Operating Income | -12.79M | -16.65M | -16.81M | -23.09M | -17.21M | |||
| Interest Income/Expense | -328.00K | -230.00K | 218.00K | -1.46M | -180.00K | |||
| Other Income/Expense | 1.67M | 2.08M | 6.58M | 6.80M | -30.00K | |||
| Non Recurring Items | -814.00K | -5.00M | N/A | N/A | N/A | |||
| Income Before Taxes | -12.27M | -19.79M | -10.01M | -17.75M | -17.42M | |||
| Income Tax | N/A | N/A | N/A | N/A | N/A | |||
| Net Income | -12.27M | -19.79M | -10.01M | -17.75M | -17.42M | |||
| EBITDA | N/A | -16.63M | -16.80M | N/A | N/A | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.58 | -1.54 | -1.93 | 0.00 | 0.00 | |||
| Non GAAP EPS | N/A | N/A | N/A | N/A | N/A | |||
| Statistics | ||||||||
All data in USD